Abstract
Severe Raynaud's phenomenon developed in a 5-year-old girl with chronic hepatitis C infection at the fifth month of interferon therapy in the absence of cryoglobulinemia and other conditions commonly associated with secondary Raynaud's phenomenon. Although interferon therapy was promptly discontinued, Raynaud's phenomenon persisted for 4 months with appearance of necrotic-ulcerous lesions at the tips of fingers.
MeSH terms
-
Blood Chemical Analysis
-
Child, Preschool
-
Cryoglobulinemia
-
Dose-Response Relationship, Drug
-
Drug Administration Schedule
-
Female
-
Follow-Up Studies
-
Hepatitis C, Chronic / diagnosis
-
Hepatitis C, Chronic / drug therapy*
-
Humans
-
Interferon alpha-2
-
Interferon-alpha / adverse effects*
-
Interferon-alpha / therapeutic use
-
Raynaud Disease / chemically induced*
-
Raynaud Disease / diagnosis*
-
Recombinant Proteins
-
Risk Assessment
-
Severity of Illness Index
-
Time Factors
-
Ultrasonography, Doppler
Substances
-
Interferon alpha-2
-
Interferon-alpha
-
Recombinant Proteins